about
Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma.Treatment options after sorafenib failure in patients with hepatocellular carcinoma.ADI-PEG 20 Plus Best Supportive Care versus Placebo Plus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma.Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibitionProspective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune TherapiesComprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for InterventionGermline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findingsImmune checkpoint inhibitors for hepatocellular carcinomaA Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced CancerSecond-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomesComparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
P50
Q47704854-30E1E2D0-1E2C-48CA-A350-BAE07DFB71AFQ47832831-C2299618-7EB0-4D0E-A1D9-18EEB1820212Q52586036-F542EB26-C5E5-4E8E-8BDF-FFF4980836F9Q57790407-5442FD94-92C7-442D-816E-492E16827448Q58101915-DBD1F886-FB71-4DDA-8649-EFE1781B0210Q88923207-BC78E5A9-C379-4157-8F00-CDB7D64EF07AQ89506007-71644EE3-D7AE-4FBB-A5A3-382383144267Q91765687-0729E0E5-7AB4-4EDC-91AE-82757DB37A5EQ92380300-4B3C9EF5-9F23-4C87-A8AA-ED3DC4EE7E6AQ92901807-EBDF17FE-457B-4AEB-BAC3-3B285D1AF307Q95336418-6B4A77D2-ACBB-4BE9-BF47-40799656469C
P50
description
researcher
@en
wetenschapper
@nl
name
Ghassan K Abou-Alfa
@en
Ghassan K Abou-Alfa
@nl
type
label
Ghassan K Abou-Alfa
@en
Ghassan K Abou-Alfa
@nl
prefLabel
Ghassan K Abou-Alfa
@en
Ghassan K Abou-Alfa
@nl
P31
P496
0000-0002-1522-8054